Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, discusses the results of an analysis conducted on a subgroup of patients with chronic lymphocytic leukemia (CLL) who progressed on pirtobrutinib after being previously treated with a covalent BTK inhibitor. Dr Patel highlights novel mutations observed in these patients, and further explains how these findings may provide valuable information on the underlying mechanisms of resistance to pirtobrutinib. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.